An Exploratory Study on Integrative Management of Irritable Bowel Syndrome with Constipation (IBS-C): Management of Irritable Bowel Syndrome with Constipation

Izrum Shafi Rajput; Warda Yawar; Syeda Javeria Ikram; Urooj Zafar; Muhammad Sajid Abbas Jaffri; Shabih Zehra

doi:10.54393/pjhs.v5i09.1724

Authors

Izrum Shafi Rajput Department of Pharmacology, Baqai Medical University, Karachi, Pakistan
Warda Yawar Department of Emergency, Patel Hospital, Karachi, Pakistan
Syeda Javeria Ikram Department of Pharmacology, Baqai Medical University, Karachi, Pakistan
Urooj Zafar Department of Pharmacology, Baqai Medical University, Karachi, Pakistan
Muhammad Sajid Abbas Jaffri Department of Medicine, Bahria University Health Sciences, Karachi, Pakistan
Shabih Zehra Department of Diagnostic Radiology, Al-Tibri Medical College, Isra University, Karachi, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i09.1724

Keywords:

Irritable Bowel Syndrome, Constipation, Mebeverine, Polyethylene Glycol

Abstract

Irritable Bowel Syndrome (IBS) was complicated disorder that results in pain and change in bowel habits. The major contributing factors to the onset and detoriation include stress and gastrointestinal problem. The women between 20 to 40 years were most commonly involved. The prevalence varies among countries that was affected by diet and diagnostic criteria. Objective: Compairing the efficacy of Mebeverine, Polyethylene Glycol with the combination therapy of Mebeverine and Polyethylene Glycol in Irritable Bowel Syndrome associated with Constipation. Methods: The comparative analytical study was conducted at the National Medical Centre, Karachi, and approved by the Ethical Review Committee of Bahria University Health Science Campus. Participants aged 15-50 with IBS were selected to reflect the target population. Observational data were collected based on the treatments they naturally received: Mebeverine, Polyethylene glycol, or a combination. Pain and constipation status were recorded at baseline (day 0) and after 24 days, analyzing the effectiveness of the treatments as they were administered in routine care settings. Results: The demographic data mentioned comparable age, weight, height, and gender distribution across the three groups. Constipation and pain status before and after varied considerably across the investigation time. There was substantial improvements by day 24 from the baseline in the combination therapy. Conclusions: The combination of Mebeverine and Polyethylene glycol reveals in managing IBS, with prominent improvements in constipation severity over the research duration. This highlights the importance of multimodal treatment methods in addressing the varied symptoms of IBS and enhancing the quality of life.

References

Zeeshan MH, Vakkalagadda NP, Sree GS, kishore Anne K, Parkash O, Fawwad SBU, et al. Irritable bowel syndrome in adults: Prevalence and risk factors. Annals of Medicine and Surgery. 2022;81:104408. DOI: https://doi.org/10.1016/j.amsu.2022.104408

Shaikh SD, Sun N, Canakis A, Park WY, Weber HC. Irritable bowel syndrome and the gut microbiome: a comprehensive review. Journal of Clinical Medicine. 2023 Mar; 12(7): 2558. doi: 10.3390/jcm12072558. DOI: https://doi.org/10.3390/jcm12072558

Midenfjord I, Borg A, Törnblom H, Simrén M. Cumulative effect of psychological alterations on gastrointestinal symptom severity in irritable bowel syndrome. Official journal of the American College of Gastroenterology| ACG. 2021;116(4):769-79. DOI: https://doi.org/10.14309/ajg.0000000000001038

Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. The lancet Gastroenterology & hepatology. 2020 Oct; 5(10): 908-17. doi: 10.1016/S2468-1253(20)30217-X. DOI: https://doi.org/10.1016/S2468-1253(20)30217-X

Bachani P, Kumar L, Kumar N, Fatima M, Naz S, Memon MK et al. Prevalence of irritable bowel syndrome and frequency of symptoms in the general population of Pakistan. Cureus. 2021 Jan; 13(1). doi: 10.7759/cureus.12541.

Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021 Jan; 160(1): 99-114. doi: 10.1053/j.gastro.2020.04.014. DOI: https://doi.org/10.1053/j.gastro.2020.04.014

Bachani P, Kumar L, Kumar N, Fatima M, Naz S, Memon MK, Memon S, Rizwan A. Prevalence of irritable bowel syndrome and frequency of symptoms in the general population of Pakistan. Cureus. 2021 Jan;13(1). DOI: https://doi.org/10.7759/cureus.12541

Byale A, Lennon RJ, Byale S, Breen-Lyles M, Edwinson AL, Gupta R et al. High-dimensional clustering of 4000 irritable bowel syndrome patients reveals seven distinct disease subsets. Clinical Gastroenterology and Hepatology. 2022 Sep.

Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling. Journal of psychosomatic research. 2022 Aug 1;159:110809. DOI: https://doi.org/10.1016/j.jpsychores.2022.110809

Videlock EJ, Chang L. Latest insights on the pathogenesis of irritable bowel syndrome. Gastroenterology Clinics. 2021 Sep 1;50(3):505-22. DOI: https://doi.org/10.1016/j.gtc.2021.04.002

Hung TH, Wang CY, Lee HF. Update in diagnosis and management of irritable bowel syndrome. Tzu Chi Medical Journal. 2023 Oct; 35(4): 306-11. doi: 10.4103/tcmj.tcmj_104_23. DOI: https://doi.org/10.4103/tcmj.tcmj_104_23

Daniluk J, Malecka-Wojciesko E, Skrzydlo-Radomanska B, Rydzewska G. The efficacy of mebeverine in the treatment of irritable bowel syndrome-A systematic review. Journal of Clinical Medicine. 2022 Feb; 11(4): 1044. doi: 10.3390/jcm11041044. DOI: https://doi.org/10.3390/jcm11041044

Lyseng-Williamson KA. Macrogol (polyethylene glycol) 4000 without electrolytes in the symptomatic treatment of chronic constipation: a profile of its use. Drugs & Therapy Perspectives. 2018 Jul; 34: 300-10. doi: 10.1007/s40267-018-0532-0. DOI: https://doi.org/10.1007/s40267-018-0532-0

Alaqeel MK, Alowaimer NA, Alonezan AF, Almegbel NY, Alaujan FY. Prevalence of irritable bowel syndrome and its association with anxiety among medical students at King Saud bin Abdulaziz University for Health Sciences in Riyadh. Pakistan Journal of Medical Sciences. 2017 Jan; 33(1): 33. doi: 10.12669/pjms.331.12572. DOI: https://doi.org/10.12669/pjms.331.12572

Quach DT, Vu KT, Vu KV. Prevalence, clinical characteristics and management of irritable bowel syndrome in Vietnam: A scoping review. Jewish General Hospital Open. 2021 Nov; 5(11): 1227-35. doi: 10.1002/jgh3.12616. DOI: https://doi.org/10.1002/jgh3.12616

Johansen SG, Ness-Jensen E. The changes in prevalence and risk of irritable bowel syndrome over time in a population-based cohort, the HUNT study, Norway. Scandinavian Journal of Gastroenterology. 2022 Feb 3:1-7. DOI: https://doi.org/10.1080/00365521.2022.2028005

Van den Houte K, Carbone F, Pannemans J, Corsetti M, Fischler B, Piessevaux H et al. Prevalence and impact of self-reported irritable bowel symptoms in the general population. United European Gastroenterology Journal. 2019 Mar; 7(2): 307-15. doi: 10.1177/2050640618821804. DOI: https://doi.org/10.1177/2050640618821804

AlButaysh OF, AlQuraini AA, Almukhaitah AA, Alahmdi YM, Alharbi FS. Epidemiology of irritable bowel syndrome and its associated factors in Saudi undergraduate students. Saudi Journal of Gastroenterology. 2020 Mar; 26(2): 89-93. doi: 10.4103/sjg.SJG_459_19. DOI: https://doi.org/10.4103/sjg.SJG_459_19

Rai RR and Nijhawan S. Comparative evaluation of efficacy and safety of drotaverine versus mebeverine in irritable bowel syndrome: A randomized double-blind controlled study. Saudi Journal of Gastroenterology. 2021 May; 27(3): 136-43. doi: 10.4103/sjg.SJG_266_20. DOI: https://doi.org/10.4103/sjg.SJG_266_20

Hatami K, Kazemi-Motlagh AH, Ajdarkosh H, Zargaran A, Karimi M, Shamshiri AR et al. Comparing the Efficacy of Cumin Sofouf With Mebeverine on Irritable Bowel Syndrome Severity and Quality of Life: A Double-blind Randomized Clinical Trial. Crescent Journal of Medical & Biological Sciences. 2020 Apr; 7(2).

Chakraborty DS, Hazra A, Sil A, Pain S. Will controlled release mebeverine be able to surpass placebo in treatment of diarrhoea predominant irritable bowel syndrome?. Journal of Family Medicine and Primary Care. 2019 Oct; 8(10): 3173-8. doi: 10.4103/jfmpc.jfmpc_522_19. DOI: https://doi.org/10.4103/jfmpc.jfmpc_522_19

Piche T and Dapoigny M. Comparative efficacy and safety of lactulose plus paraffin vs polyethylene glycol in functional constipation: a randomised clinical study. United European Gastroenterology Journal. 2020 Oct; 8(8): 923-32. doi: 10.1177/2050640620937913. DOI: https://doi.org/10.1177/2050640620937913

Safarpour H, Imanieh MH, Asmarian N. Single Dose or Divided Dose of Polyethylene Glycol in Treatment of Pediatric Functional Constipation: A Randomized Clinical Trial. 2021 Oct. doi: 10.21203/rs.3.rs-977795/v1. DOI: https://doi.org/10.21203/rs.3.rs-977795/v1

Rawla P, Sunkara T, Raj JP. Updated review of current pharmacological and non-pharmacological management of irritable bowel syndrome. Life Sciences. 2018 Nov; 212: 176-81. doi: 10.1016/j.lfs.2018.10.001. DOI: https://doi.org/10.1016/j.lfs.2018.10.001